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Chronic obstructive pulmonary disease (COPD) a term based on the demonstration of irre-
versible airways obstruction, introduced to unify a range of chronic progressive diseases
of the airways consequent upon inhalation of toxins. While disease is initiated and pro-
gressed by inhaled toxins, an additional pathway of damage has emerged, with particular
relevance to acute exacerbations. Exacerbations of disease due to an increase in the level
of intrabronchial inﬂammation have taken on a new signiﬁcance as their role in determining
both acute and chronic outcomes is better understood.This “second pathway” of disease
is a consequence of bacterial colonization of damaged airways. Although bacteria have
been linked to acute episodes in COPD over 50years, only recently has quality data on
antibiotic usage and the detection of “exacerbation isolates” of non-typeable Haemophilus
inﬂuenzae (NTHi) provided strong argument in support of a pathogenic role.Yet a poor cor-
relation between detection of colonizing bacteria and clinical status remained a concern
in attempts to explain a role for bacteria in a classical infection model. This presentation
discusses a hypothesis that acute exacerbations reﬂect aT cell-dependent hypersensitivity
response to colonizing bacteria, with IL -17 dependent accumulation of neutrophils within
the bronchus, as the main outcome measure. Critical protection against exacerbations fol-
lowing oral administration of NTHi, an immunotherapy that drives aTH17T cell response
from Peyer’s patches, reduces the load of intrabronchial bacteria while preventing access
of inhaled bacteria into small airways. Immunotherapy augments a physiological “loop”
based on aspiration of bronchus content into the gut. A second “hypersensitivity” mecha-
nism may cause bronchospasm – in both COPD and treatment-resistant asthma – due to
speciﬁc IgE antibody directed against colonizing bacteria, as oral NTHi abrogates wheeze
in subjects with recurrent “wheezy bronchitis.”
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INTRODUCTION
Chronic obstructive pulmonary disease (COPD) has a long his-
tory of neglect,being seen as a self-induced lung disease of elderly
smokers for which little could be done. Recognition of the extent
of personalandeconomiccostsof thediseasetogetherwithdetec-
tion of inﬂammation as a process relevant to disease progression,
has heightened interest in COPD and encouraged new strate-
gies for disease control (Barnes, 2008). The term “COPD” was
introduced to unify divergent opinion about smoking-related air-
waysdisease(SRAD),focusingonirreversibleairwaysobstruction
deﬁned by spirometry as the common denominator (Briscoe and
Nash,1965).Inthe1950sand1960sopinionwasdividedacrossthe
Atlantic. In the USA interest concentrated on the structural and
functional outcomes of toxin inhalation (Petty, 2006), whereas
in the UK experience was inﬂuenced by epidemiological analysis
of smog-related bronchitis (Fletcher and Peto, 1977). These latter
studiesrecognizedproductivecough(simplebronchitis),frequent
chest illnesses (infective bronchitis), and impairment of venti-
lating capacity (obstructive bronchitis; Fletcher and Peto, 1977).
The British view was that inhaled toxin-induced hypersecretion
encouraged infection which damaged bronchi and lungs caus-
ing “obstructive bronchitis” and emphysema (Fletcher and Peto,
1977). At the same time, argument existed for and against the
ideathatasthmaandCOPDreﬂecteddifferentextremesof acom-
mon airways disease (known as the “Dutch Hypothesis”; Kraft,
2006). There was only limited support for bacterial infection as
a cause of acute episodes came from microbiological, serological,
and antibiotic studies (Tager and Speizer, 1975). The candidate
pathogens identiﬁed most commonly from sputum cultures were
non-typeable Haemophilus inﬂuenzae (NTHi) and Streptococcus
pneumoniae (May, 1953). When Fletcher failed to demonstrate
that “infection” episodes inﬂuenced change in chronic airﬂow
obstruction (Fletcher and Peto, 1977), support waned for bac-
terial colonization as a contributory cause of airways damage in
COPD. Interest both sides of the Atlantic was in toxin inhala-
tion as the cause of the intrabronchial inﬂammatory response.
A recent British review of airway inﬂammation in COPD saw this
response only in terms of smoking (Barnes, 2008). Twenty-ﬁve
years ago, the view that bacteria were not a signiﬁcant “driver”
of intrabronchial inﬂammation in COPD was challenged when
www.frontiersin.org March 2011 | Volume 2 | Article 7 | 1Clancy and Dunkley Control of acute exacerbations in COPD with NTHi
subjects with moderate–severe COPD had a signiﬁcant reduc-
tion in both positive sputum cultures and frequency of “acute
episodes” following oral immunization with inactivated NTHi
(Clancy et al., 1985). No increase in speciﬁc IgA was detected
in secretions, which at the time was the mechanism expected to
prevent the downward spread of pathogens from the upper air-
ways (Clancy et al., 1985). At the time, the reduction in incidence
of exacerbations following oral immunization with NTHi had no
impact on the view that inhaled toxins were sufﬁcient to account
for COPD. Currently there has been a revision of the view that
bacteriaplaylittleroleinthepathogenesisof COPD,basedonbet-
terqualityantibiotictrialsanddetectionof“exacerbationisolates”
of NTHi (Sethi and Murphy, 2008; Sethi et al., 2008). Sethi and
his colleagues have proposed a“vicious cycle”hypothesis whereby
primary damage to airways leads to bacterial colonization, with
addeddamagebegettingdamage(SethiandMurphy,2008).While
bacteria may directly contribute to airways disease (Sethi et al.,
2008), current theories still inadequately explain the poor “ﬁt”
between microbiological and clinical data. For example, isolation
of “pathogens”from sputum collected in an exacerbation is simi-
lar to the pattern obtained in specimens from stable disease (Butt
et al., 1990; Sethi et al., 2007). We review a hypothesis that has
acute exacerbations of COPD reﬂecting a particular balance of
the host–parasite relationship involving NTHi and the mucosal
immune response. Thus exacerbations occur as an uncontrolled
and inappropriate inﬂammatory response to bacteria colonizing
damaged airways due to an ineffective Peyer’s patch-derived T
lymphocyte response. A corollary to this hypothesis is that oral
immunization with NTHi improves the efﬁciency of gut-derived
bronchusprotection,withaconsequentreductioninthefrequency
and severity of exacerbations of COPD.
THE HYPOTHESIS
Current thinking as well as changes in management strategies
in COPD have largely ﬂowed from the “asthma” model, sub-
stituting the neutrophil for the eosinophil as the dominant cell
type in the intrabronchial inﬂammatory exudate (Barnes, 2008).
As a consequence, search for new therapies has focused on key
regulatory molecules and cells in inﬂammation. The key ques-
tions become:“To what extent is inﬂammation the cause of dam-
age?” and “What are the drivers of this inﬂammatory response?”
Directing therapy toward removal of the stimulus of inﬂamma-
tion has the advantages of avoiding the complications of both
drug-induced immune suppression, and broad based suppres-
sion of the inﬂammatory process. We discuss a hypothesis that
focuses on a host–parasite relationship involving colonizing bac-
teria and the mucosal immune response where the balance of this
relationship determines the level of intrabronchial inﬂammation.
An acute shift in the balance leads to an excessive inﬂamma-
tory response. If this exceeds a threshold it is detected clinically
as an “acute exacerbation.” Simply put, an acute exacerbation of
COPDisahypersensitivityresponse,involvingantigensandeffec-
tor immune responses (particularly Th17 CD4+ T cells) within
the mucosal compartment. A corollary of this hypothesis is that a
shift favoring host mucosal protection would buffer against acute
exacerbations.Aswithanyhypersensitivityreaction,itistheinap-
propriate and excessive production of components of the innate
immune system, beyond that which is directed against pathogens
and which is therefore protective, that cause non-speciﬁc tar-
get damage. The sequence of events in the proposed model is
summarized in Figure 1:
(I) Inhalationoftoxinsdamagebronchusmucosa:Thishasbeen
well documented and requires no further discussion.
(II) Bacterial colonization and antigen presentation to gut-
associated lymphoid tissue (GALT): It has been long rec-
ognized that damaged bronchus mucosa becomes colonized
by bacteria, most commonly NTHi (Butt et al., 1990; Sethi
etal.,2007)andwhenpresentNTHirepresentthemajorityof
bacterial isolates (Butt et al., 1990). Argument has centered
on the signiﬁcance of these bacteria with respect to acute
exacerbations, the question often framed in terms of “col-
onization” versus “infection.” Recent reviews conclude that
a link exists between colonization and acute exacerbations,
FIGURE1|P r oposed sequence of events in pathogenesis of COPD.
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claiming that 30–50% of acute exacerbations are due to
bacterial infection (Sethi and Murphy, 2008). Uncertainty
about these conclusions, however, comes from concern that
the infection parameters assessed are more appropriate to
invasive monobacterial infection, and there are notorious
difﬁcultiesinobtainingreproducibleandrepresentativespu-
tumsamples.Of importancewastheobservationthatdetec-
tion of pathogens in sputum varied little between acute
exacerbations and chronic disease (Butt et al., 1990; Sethi
et al., 2007), which is not consistent with invasive infection.
Quantitative analysis showed little difference in density of
colonization in acute and stable disease (Butt et al., 1990;
Lehmann et al., 1991), requiring a review of the mechanism
whereby bacteria contribute to inﬂammation. Sputum cul-
tures underestimate the true incidence of colonization given
the results of cultures from bronchial brush samples (Bandi
et al., 2001), and recent molecular analysis of lower airways
secretionswhichsuggestnearlyallwithCOPDarecolonized
with NTHi. Aspiration of bronchus content may deliver up
to 1011 live bacteria per day into the gut (Lehmann et al.,
1991). A prospective study in smokers over a winter period
showed a signiﬁcant seasonal increase in antigen-reactive T
cells,consistentwiththeideathatswallowedsputumleadsto
antigen presentation to the GALT as a physiological mecha-
nism of antigen handling (Clancy and Dunkley, 2010). This
was the ﬁrst evidence that bronchus protection is a conse-
quenceofantigenhandlingviathegut,emphasizingacritical
role for the common mucosal system in man.
(III) Controlled inﬂammation: Central to the hypothesis is iden-
tiﬁcation of antigen (bacteria) within the bronchus lumen
where it interacts with a mucosal immune response. Only
if these bacteria penetrate as far as the small airways and
the broncho-alveolar apparatus, is a serum IgG antibody
detected. The classical “marker” of local immunity, an
IgA antibody response, is downregulated in subjects with
mucosaldamageandinﬂammation(Clancyetal.,1995).The
key effector mechanism responsible for control of mucosal
colonization is T cell-dependent recruitment and activa-
tion of neutrophils, and secretion of antibacterial factors
(Khader et al., 2009). These T cells are generated in the
GALT and transit to the bronchus mucosa as a compo-
nent of the common mucosal system (Wallace et al., 1989,
1991; Dunkley et al., 1994, 1995). Secondary stimulation
by colonizing bacteria of T cells relocated to the bronchus
mucosa may be required if the immunogenic signal to the
GALT is weak (Wallace et al., 1989, 1990, 1991). T cell-
activated neutrophils within sputum undergo phenotypic
change characterized by secretion of large amounts of IL-
8 and TNFα, and increased phagocytic capacity. Viability
is maintained by an autocrine loop involving IL-1 (Pang
et al.,1997). Recent Studies on the mucosal immune system
have focused on regional induction and effector mucosal
sites as a “sub-network” with particular “homing” of B-
and T-lymphocytes determined by chemokines, integrins,
and cytokines that are differentially expressed between the
mucosaltissues(OtczykandCripps,2010).Thisreviewsum-
marizes the current but limited knowledge with respect to
the airways including potential roles for CD62L, α4B1 inte-
grin, and LFA-1 adhesion pathways (Xu et al., 2003), and
the importance of antigen at target mucosal sites (Qimron
et al.,2004). The importance of dendritic cells and secretion
of retinoic acid in the production of mucosa – imprinting
homing molecules has been described (Iwata et al., 2004)
and speciﬁc dendritic cells direction TH17 cells homing to
the airways have been identiﬁed (Khader et al., 2009).
Theconceptof“balance”ofthehost–parasiterelationship
being relevant to acute exacerbations is supported by study
of subjects with an exacerbation-prone phenotype. These
subjects have more cell-attached bacteria, and a reduced
lysozyme level in secretions (Taylor et al.,1990;Clancy et al.,
1995).Thuschronicinﬂammationwithintheairwaysinpart
involves a direct T cell/neutrophil response to colonizing
bacteriaand,indirectly,apersistenceofactivatedneutrophils
maintainedbyautocrinemechanisms.Theroleofgut-driven
Th17 cells is critical to mucosal protection through recruit-
mentof neutrophilsandthesecretionof antibacterialfactors
from the bronchus epithelium, with detection of IL-17 in
sputum,and Th17 cells in the draining nodes (Khader et al.,




continue to smoke (Tandon et al., 2010), hypersensitivity
to persistent bacteria within the airways is a credible expla-
nation for continuing intrabronchial inﬂammation. Recent
studies in emphysema identify phenotypic changes in den-
driticcellsobtainedfromresectedlungfromex-smokersthat
driveTh1andTh17cells(Shanetal.,2009),andasigniﬁcant
increase in IL-17, IL-22, and IL-23 positive immunoreac-
tive cells within the bronchial mucosa (Shan et al., 2009),
whileintestinalimmunizationof ratswithinactivatedNTHi
increasesspeciﬁcTh17cellsinbothmesentericlymphnodes
and in airways (Figure 2).
(IV) Shifts in the host–parasite relationship: Acute exacerba-
tion: (shift favors parasite). Acute exacerbations of COPD
are periods of accentuated intrabronchial inﬂammation
(Wedzicha and Seemungal, 2007) due to a failure of the
host to contain colonizing bacteria,causing an excessive and
inappropriate inﬂammatory response. Increase in inﬂam-
mation may follow acquisition of pathogenic “exacerba-
tion” isolates of NTHi (Sethi et al., 2008), other bacterial
pathogens, or an increase in resident bacteria due to an
intercurrent virus infection (Sethi and Murphy, 2008). Co-
infection of mice with NTHi and inﬂuenza virus increases
titer of bacteria 100-fold and virus 10-fold (Dunkley and
Clancy,1997). These observations support the idea that col-
onizing bacteria in COPD are a common denominator of
acute exacerbations, by upregulation of antigenic stimulus
directly due to acquisition of novel “exacerbation” strains
of bacteria, or indirectly as a consequence of a virus infec-
tion. Bronchus brush biopsy analysis conﬁrms a difference
in colonization level with 33% of stable COPD samples pos-
itive for NTHi compared to 87% of biopsies taken during
an exacerbation (Bandi et al., 2001). Clinical studies show a
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FIGURE2|I L - 1 7 Ap r oduced by in vitro re-stimulated mesenteric lymph
node (MLN) lymphocytes and detected in broncho-alveolar lavage ﬂuid
following intestinal immunization with killedNTHi. (A) IL -17 produced by
re-stimulated MLN (lymphocytes) following oral immunization of C57BL/6
mice with killed whole cells of NTHi. (B) IL -17 in C57BL/6 mouse lung
following oral immunization with killed whole cells of NTHi.
subtle but signiﬁcant increase in colonizing bacteria dur-
ing exacerbations (Sethi et al., 2007). Damage is due to
direct toxicity by pathogenic bacteria (Sethi et al., 2008),
andtheinappropriateandexcessiverecruitmentof activated
neutrophils (Wallace et al., 1990; Wedzicha and Seemun-
gal, 2007). This conclusion is supported by the presence
in sputum of increased levels of neutrophils, IL-8, TNFα,




bacteria, any therapy improving the efﬁciency of host protection
should reduce their frequency and severity. Reduction in coloniz-
ing pressure reduces the level of intraluminal inﬂammation below
threshold levels for “severe” exacerbations before falling below a
lower threshold for“any exacerbation”– hence a dominant effect
on reducing severity of episodes (Figure 3).
IMMUNOTHERAPY WITH ORAL NTHi (SHIFT FAVORS HOST)
Reduction in frequency and severity of exacerbations in COPD,
and in reduction of pathogens in sputum following speciﬁc oral
immunotherapywithoralNTHi,arestrongargumentsinsupport
of the postulate that colonizing bacteria play a critical role in the
pathogenesis of acute exacerbations. Results from four published
trials (Clancy et al., 1985; Clancy et al., 1990; Lehmann et al.,
1991; Tandon and Gebski, 1991) showed a reduction in exacerba-
tions(deﬁnedasanincreaseinvolumeandpurulenceof sputum),
and reduced use of antibiotics. These were the basis of a pos-
itive Cochrane Report (Foxwell et al., 2006). A recent study in
severe COPD showed a reduction in total exacerbations of 16%,
butwhenexacerbationsweredeﬁnedintermsof arequirementfor
therapeutic intervention (capturing the more severe episodes), a
signiﬁcantreductionof 63%(corticosteroid-treatedpatients),and
90% (hospital-treated) followed oral NTHi immunization (Tan-
don et al., 2010). This “shift” toward more severe exacerbations
wouldbeexpectedif oralNTHireducedthelevelof intrabronchial
inﬂammation in the majority of recipients. Further, quantitative
bacteriology of sputum following oral NTHi noteda3l o gr e d u c -
tion in bacteria (Lehmann et al.,1991),and reduction involved all
pathogens (Tandon and Gebski, 1991; Tandon et al., 2010). Non-
speciﬁc effector function based on phagocytosis is responsible for
reduction of all pathogens. Oral immunization of smokers with
NTHi prevents inhaled NTHi from penetrating into terminal air-
ways (Clancy and Dunkley, 2010). In this latter study, protection
correlated with an enhanced circulating speciﬁc antigen-reactive
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FIGURE 3 | Diagrammatic representation of aspiration of bronchus
content (including bacteria) into gut (1) to stimulate Peyer’s patches (3)
to releaseT-lymphocytes which “home” to the bronchus (4) where
they – directly or indirectly – secrete cytokines and chemokines
which augment recruitment and activation of phagocytes (5) which
reduce colonizing load of damaged bronchus mucosa. Ingestion of
inactivated non-typeable Haemophilus inﬂuenzae (2) augments this
protective “loop” .
T cell response and a reduction in level of salivary lysozyme, a
marker of luminal inﬂammation in COPD (Clancy and Dunkley,
2010). These human studies follow the demonstration in rodents
that speciﬁc T cells obtained from thoracic duct drainage after
Peyer’s patch immunization with NTHi, can transfer accelerated
clearance of bacteria from the bronchus (Clancy et al., 1995).
OralimmunizationwithNTHiof miceco-infectedwithinﬂuenza
virus and NTHi abrogated the increase in titer of both microbes
(Dunkley and Clancy, 1997), indicating that colonizing NTHi
can amplify the inﬂammatory response to virus infections.
Thus by reducing the level of colonization, oral immuniza-
tion with NTHi protects against infection initiated by bac-
teria and viruses. It is unclear as to whether most subjects
with COPD require re-stimulation of T cells migrating to the
bronchi by colonizing bacteria as recent data suggests most




that on one hand drivesaTc e l lr e s p o n s ef o l l o w i n gaspiration of
bronchus content into the gut, while on the other is the target of
that response. The outcome is determined by the extent of the
a n t i g e nl o a d–al o wa n t i g e nl o a dr e ﬂ e c t sp r o t e c t i o na n dc o ntain-
ment of infection by T cell-activated phagocytosis, while a high
load reﬂects ineffective containment and a hypersensitivity reac-
tion (seen clinically as an acute exacerbation). An upward shift in
antigen occurs by inhaling novel“exacerbation” isolates of bacte-
ria (in particular NTHi; Sethi et al., 2008) or following a virus
infection, in particular inﬂuenza (Dunkley and Clancy, 1997).
These ideas place bacteria – especially NTHi – on a ﬁnal common
pathway that determines the level of intrabronchial inﬂammatory
exudate. Progression of COPD and exacerbations occur whether
ornotthereiscontinuedinhalationoftoxicmaterial.Thishypoth-
esis can be tested using quantitative cellular and molecular assays
of bronchial biopsies and broncho-alveolar washings, to ana-
lyze the host–parasite relationship as it pertains to the Th17
response to colonizing bacteria (and associated inﬂammation)
in subjects with stable COPD, with an acute exacerbation, and
following immunotherapy with oral NTHi. Oral immunother-
apy with NTHi augments antigen delivery to the Peyer’s patches,
with a consequent increase in T cells delivered to the mucosa,
increasing the efﬁciency of phagocytosis. Protection is refected in
a reduction in the load of bacteria colonizing damaged bronchi,
reﬂecting a “shift” in outcome away from the hypersensitivity
pro-inﬂammatory response characteristic of a less efﬁcient T cell
response.
Clinical studies demonstrate a new approach to management
of one of the major unmet medical needs, while providing strong
evidence that abnormal colonization of airways plays a signiﬁcant
roleinthepathogenesisof exacerbationsof COPD.Importantand
effective strategies for controlling mucosal infection through oral
immunization have likely been neglected due to an inappropriate
focus on IgA antibody as a monitor of vaccine efﬁcacy.
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